摘要
目的 探究BCR-ABL融合基因在诊断慢性粒细胞白血病(CML)及临床分期的价值。方法 回顾性分析近年本院收治的59例CML患儿的临床资料,以对比分析CML与健康儿童的BCR-ABL融合基因突变率及不同分期BCR-ABL突变率。结果 观察组BCR-ABL突变率为89.8%,而对照组为阴性(P<0.01);CML慢性期、缓解期、加速期、急变期的BCR-ABL突变率分别为96.8%、25.0%、85.7%、100.0%。结论 BCR-ABL融合基因可作为CML诊断及分期的重要检测指标,对临床诊断、并根据临床分期指导治疗有积极价值。
Objective To explore the value of BCR-ABL fusion gene in the diagnosis of chronic myeloid leukemia(CML)and clinical staging.Methods The clinical data of 59 children with CML admitted to our hospital in recent years were analyzed retrospectively.The mutation rates of BCR-ABL fusion gene and BCRABL mutation rates in different stages were compared between CML and healthy children.Results The mutation rate of BCR-ABL in the observation group was 89.8%,while that in the control group was negative(P<0.01);the mutation rates of BCR-ABL in chronic phase,remission phase,acceleration phase,and acute phase were 96.8%,25.0%,85.7%,and 100.0%respectively.Conclusion BCR-ABL fusion gene can be used as an important marker for the diagnosis and staging of CML,and has positive value for clinical diagnosis and treatment according to clinical staging.
作者
王金
Wang Jin(Children’s Hospital Affiliated to Zhengzhou University,Henan Provincial Key Laboratory of Children’s Genetics and Metabolic Diseases,Zhengzhou Children’s Hospital,Zhengzhou 450018,China)
出处
《国际医药卫生导报》
2019年第2期225-227,共3页
International Medicine and Health Guidance News
